BioSpace News Archive

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report third quarter financial results on Wednesday, November 9, 2022, at 8:30 a.m. ET.

BeiGene Receives European Commission Approval for BRUKINSA ® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma.

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2022.

Alterome Therapeutics, Inc. today announced that it has raised more than $35 million in a Series A2 financing, bringing total funds raised to nearly $100 million.

CareDx, Inc. today announced that it will be sharing the latest data on AlloSure® Kidney and its patient-centered digital health solutions at the American Society of Nephrology (ASN) Kidney Week 2022 meeting being held November 3 - 6 in Orlando, Florida.

Antibe Therapeutics Inc is pleased to announce the closing of the sale of its Citagenix Inc. subsidiary to HANSAmed Limited (“HANSAmed”), a leading Canadian distributor of pharmaceuticals and medical devices to dental professionals.

Elite Pharmaceuticals, Inc. today reported positive results from pivotal fed and fasted bioequivalence studies for an undisclosed extended-release generic drug product in a class of medications called dopamine agonists.

U.S. Food and Drug Administration Approves Vemlidy ® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients.

LumiraDx Limited (Nasdaq: LMDX ), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter financial results on Wednesday, November 9th , 2022.

Can-Fite BioPharma announced today the Company’s CEO, Dr. Pnina Fishman, will deliver a presentation titled “Piclidenoson for the Treatment of Psoriasis: Clinical Development and Mechanism of Drug Action” at the 6th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases on November 2, 2022.